EXPLORE THE UNIVERSITY OF OXFORD'S WORLD-CLASS RESEARCH

1 - 2 of 2
1
Conference item icon
Conference item

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free

  • Coates, LC, Ritchlin, CT, Gossec, L, et al.
  • 2021-05-19
File not available icon
Not peer reviewed icon
Link to publisher copy available icon
2
Conference item icon
Conference item

Guselkumab-treated patients with psoriatic arthritis achieved clinically meaningful improvements in general health outcomes measured with PROMIS-29 through 52 weeks: results from the phase 3 DISCOVER-1 trial

  • Orbai, AM, Coates, LC, Deodhar, A, et al.
  • 2021-05-19
File not available icon
Peer reviewed icon
Link to publisher copy available icon
FILTER RESULTS

TO TOP